Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Assets Average: 2020-2025

Historic Assets Average for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to $514.8 million.

  • Tarsus Pharmaceuticals' Assets Average rose 36.70% to $514.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $514.8 million, marking a year-over-year increase of 36.70%. This contributed to the annual value of $321.2 million for FY2024, which is 30.23% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Assets Average of $514.8 million as of Q3 2025, which was up 3.40% from $497.9 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Assets Average peaked at $514.8 million during Q3 2025, and registered a low of $180.2 million during Q1 2022.
  • Over the past 3 years, Tarsus Pharmaceuticals' median Assets Average value was $363.1 million (recorded in 2024), while the average stood at $344.6 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Assets Average decreased by 7.87% in 2023, and later spiked by 81.47% in 2024.
  • Tarsus Pharmaceuticals' Assets Average (Quarterly) stood at $184.7 million in 2021, then climbed by 25.73% to $232.2 million in 2022, then grew by 14.97% to $266.9 million in 2023, then surged by 41.11% to $376.6 million in 2024, then skyrocketed by 36.70% to $514.8 million in 2025.
  • Its Assets Average stands at $514.8 million for Q3 2025, versus $497.9 million for Q2 2025 and $438.9 million for Q1 2025.